National Institutes of Health to Consider Exclusive Patent License for Biomarkers for Acute Ischemic Stroke

Summary

The National Institutes of Health is seeking to grant a co-exclusive patent license to CereDx, Inc. for the use of biomarkers for acute ischemic stroke, as outlined in a U.S. patent application filed in 2012.